©2024 Stanford Medicine
Altitude Sickness Prevention and Efficacy of Comparative Treatments
Not Recruiting
Trial ID: NCT02604173
Purpose
This study is designed to be the first to examine the novel drug budesonide for prevention of
acute mountain sickness in comparison to acetazolamide and in the context of rapid ascent to
high altitude. The investigators will accomplish these objectives with a prospective, double
blinded view of a large population of hikers who are ascending at their own rate in a true
hiking environment.
Official Title
A Randomized Controlled Trial of Altitude Sickness Prevention and Efficacy of Comparative Treatments
Eligibility
Inclusion Criteria:
1. Male and Female
2. Sea level-dwelling hikers
3. Between ages 18-65
Exclusion Criteria:
1. History of allergy to acetazolamide or budesonide (or other corticosteroids)
2. Taken NSAIDs, acetazolamide, or corticosteroids in the one week prior to study
enrollment.
3. Hazardous medical conditions which precludes the ability to moderately hike to high
altitude including: sickle cell anemia, asthma, or COPD, severe anemia, or severe
coronary arterial disease.
4. Pregnancy or suspected pregnancy.
5. Participants who are younger than 18 years of age and more than 65
6. Sleep above 4'000 elevation in the preceding 1 week.
7. History of asthma or COPD
8. Current symptoms of an acute upper respiratory illness.
9. Unable to complete a moderately strenuous hike at high altitude.
Intervention(s):
drug: Budesonide
drug: Acetazolamide
drug: Placebo
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Grant S Lipman, MD
415-290-9286